Skip to main content


Figure 2 | Breast Cancer Research

Figure 2

From: Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer

Figure 2

siRNA screen for genes that promote proliferation of MDA-MB-231 cells identify CHK1, RRM1 and RRM2 as top-hits. (A) Effects on proliferation by gene knockdown with the custom siRNA library. Data are shown as a z-score distribution from the mean. (B) Percent change (from non-targeting siRNA (NTS) control) in proliferation of cells due to knock-down of expression by individual siRNA oligos for the genes noted. Q-RT-PCR determination of reduced RNA (C) and protein (D) expression for CHK1, RRMI, and RRM2 for individual siRNA oligos. (E) Percent growth of cells due to expression of Qiagen CHK1-siRNA. Gene (F) and protein (G) expression for CHK1 is suppressed in cells that are transfected with individual Qiagen CHK1-siRNAs. Graphs shown are representative of 3 repeated experiments.

Back to article page